Kymera Therapeutics (KYMR) Financials: History & Chart

Kymera Therapeutics, Inc.(KYMR)

Biotechnology · Watertown, MA

$104.38-5.47 (-4.98%)

Delayed quote: Oct 6, 2026, 12:35 PM EDT

About Kymera Therapeutics, Inc.

Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing pioneering small molecule therapeutics. These treatments operate by harnessing the body's inherent protein degradation system to selectively eliminate disease-causing proteins. The company's pipeline features several programs, including the IRAK4 program, currently in Phase I clinical trials, which targets various immunology-inflammation disorders such as hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, generalized pustular psoriasis, and rheumatoid arthritis. Additionally, Kymera is advancing its IRAKIMiD program, designed to address MYD88-mutated diffuse large B cell lymphoma. Other key programs include the STAT3 program, focused on hematological malignancies, solid tumors, autoimmune diseases, and fibrosis, as well as the MDM2 program, which is also aimed at hematological malignancies and solid tumors. The company was founded in 2015 and maintains its headquarters in Watertown, Massachusetts.

Watertown, MA

273 employees

www.kymeratx.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Nello Mainolfi

View full financials

Financials

SEC Filings

Quarterly Income Statement (USD)

Swipe horizontally to review earlier periods. The line-item column stays pinned.

Quarterly Report	TTM	Quarter ended Jun 2026	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024
Revenue	104.99M	65.00M	34.37M	2.86M	2.76M	11.48M	22.10M	7.39M	3.74M
Cost of Goods Sold	-2.08M	0.00	0.00	-76.18M	74.09M	2.08M	0.00	0.00	0.00
Gross Profit	107.07M	65.00M	34.37M	79.04M	-71.33M	9.39M	22.10M	7.39M	3.74M
Gross Profit Margin	102.0%	100.0%	100.0%	2763.6%	-2580.7%	81.8%	100.0%	100.0%	100.0%
Total Operating Expenses	457.25M	140.61M	118.52M	176.93M	21.19M	93.95M	96.53M	88.15M	75.86M
Research & Development	375.60M	119.48M	98.16M	83.86M	74.09M	78.39M	80.25M	71.82M	60.41M
Selling, General & Administrative	75.77M	21.13M	20.36M	16.95M	17.34M	17.64M	16.27M	16.33M	15.46M
Operating Income (EBIT)	-350.18M	-75.61M	-84.15M	-97.90M	-92.52M	-84.56M	-74.43M	-80.75M	-72.12M
Operating Margin	-333.5%	-116.3%	-244.9%	-3422.9%	-3347.4%	-736.8%	-336.8%	-1092.2%	-1927.9%
Income Before Tax (EBT)	-299.87M	-61.21M	-69.23M	-87.25M	-82.17M	-76.61M	-65.58M	-70.75M	-62.49M
Interest Income	50.52M	14.48M	14.98M	10.71M	10.35M	8.05M	8.92M	10.06M	9.70M
Interest Expense	211K	81K	61K	69K	N/A	108K	72K	59K	60K
Other Income/Expense	50.30M	14.40M	14.92M	10.64M	10.35M	7.94M	8.85M	10.00M	9.64M
Net Income	-299.65M	-61.21M	-69.23M	-87.03M	-82.17M	-76.61M	-65.58M	-70.75M	-62.49M
Income Tax Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Profit Margin	-285.4%	-94.2%	-201.5%	-3043.0%	-2973.0%	-667.6%	-296.7%	-956.9%	-1670.3%
EBITDA	-341.25M	-73.58M	-82.13M	-95.86M	-89.67M	-82.47M	-72.38M	-78.77M	-70.14M
EBITDA Margin	-325.0%	-113.2%	-239.0%	-3351.9%	-3244.3%	-718.7%	-327.5%	-1065.3%	-1874.8%
Depreciation & Amortization	8.93M	2.03M	2.02M	2.03M	2.85M	2.08M	2.05M	1.99M	1.99M
EPS Basic	-3.25	-0.62	-0.71	-0.98	-0.94	-0.95	-0.82	-0.88	-0.82
EPS Diluted	-3.25	-0.62	-0.71	-0.98	-0.94	-0.95	-0.82	-0.88	-0.82
Weighted Average Basic Shares	98.18M	98.18M	97.53M	84.39M	87.30M	80.45M	80.15M	79.99M	76.13M
Weighted Average Diluted Shares	98.18M	98.18M	97.53M	84.39M	87.30M	80.45M	80.15M	79.99M	76.13M

Annual Income Statement (USD)

Swipe horizontally to review earlier years. The line-item column stays pinned.

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Revenue	39.20M	47.07M	78.59M	46.83M	72.83M	34.03M	2.93M	0.00
Cost of Goods Sold	0.00	0.00	0.00	0.00	0.00	0.00	825K	205K
Gross Profit	39.20M	47.07M	78.59M	46.83M	72.83M	34.03M	2.11M	-205K
Gross Profit Margin	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	71.9%	N/A
Total Operating Expenses	388.60M	308.71M	244.12M	208.08M	173.36M	80.34M	45.14M	21.45M
Research & Development	316.60M	240.25M	189.08M	164.25M	137.02M	62.10M	37.16M	17.68M
Selling, General & Administrative	68.20M	63.53M	55.04M	43.83M	36.34M	18.23M	7.98M	3.77M
Operating Income (EBIT)	-349.40M	-261.63M	-165.53M	-161.26M	-100.53M	-46.30M	-42.20M	-21.45M
Operating Margin	-891.3%	-555.8%	-210.6%	-344.4%	-138.0%	-136.1%	-1438.5%	N/A
Income Before Tax (EBT)	-311.62M	-223.86M	-146.96M	-154.81M	-100.22M	-45.59M	-41.25M	-21.47M
Interest Income	38.03M	38.03M	18.76M	6.62M	488K	826K	1.00M	N/A
Interest Expense	249K	249K	196K	176K	175K	115K	46K	16K
Other Income/Expense	37.78M	37.78M	18.57M	6.45M	313K	711K	959K	-16K
Net Income	-311.40M	-223.86M	-146.96M	-154.81M	-100.22M	-45.59M	-41.29M	-21.47M
Income Tax Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	44K
Net Profit Margin	-794.4%	-475.6%	-187.0%	-330.6%	-137.6%	-134.0%	-1407.4%	N/A
EBITDA	-341.09M	-254.26M	-161.97M	-158.28M	-98.13M	-44.54M	-41.38M	-21.25M
EBITDA Margin	-870.1%	-540.2%	-206.1%	-338.0%	-134.7%	-130.9%	-1410.4%	N/A
Depreciation & Amortization	8.31M	7.37M	3.56M	2.98M	2.40M	1.76M	825K	205K
EPS Basic	-3.69	-2.98	-2.52	-2.87	-2.09	-0.99	-0.93	-0.48
EPS Diluted	-3.69	-2.98	-2.52	-2.87	-2.09	-0.99	-0.93	-0.48
Weighted Average Basic Shares	84.39M	75.04M	58.37M	53.93M	47.99M	44.56M	44.53M	44.53M
Weighted Average Diluted Shares	84.39M	75.04M	58.37M	53.93M	47.99M	44.56M	44.53M	44.53M

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.